Editing Transdermal patch (section)

==Applications==
* The highest selling transdermal patch in the United States is the [[nicotine patch]], which releases [[nicotine]] in controlled doses to help with cessation of [[tobacco smoking]]. The first commercially available vapour patch to reduce smoking was approved in Europe in 2007.
* Two [[opioid]] medications used to provide round-the-clock relief for severe pain are often prescribed in patch form, [[fentanyl]] CII (marketed as [[Duragesic]]) and [[buprenorphine]] CIII (marketed as [[Buprenorphine|BuTrans]]).
* Hormonal patches:
** [[Estrogen patch]]es are sometimes prescribed to treat [[menopause|menopausal]] symptoms (as well as post-menopausal [[osteoporosis]]) and to [[transgender women]] as a type of [[Hormone replacement therapy (male-to-female)|hormone replacement therapy]].
** [[Contraceptive patch]]es (marketed as [[Ortho Evra]] or [[Ortho Evra|Evra]]) and 
** [[testosterone (patch)|Testosterone]] CIII patches for both men (Androderm) and women (Intrinsa).
* [[Nitroglycerin]] patches are sometimes prescribed for the treatment of [[Angina pectoris|angina]] in lieu of [[sublingual administration|sublingual pills]].
* Transdermal [[Hyoscine hydrobromide|scopolamine]] is commonly used as a treatment for [[motion sickness]].<ref name="pmid16719539">{{cite journal |vauthors=Nachum Z, Shupak A, Gordon CR |title=Transdermal scopolamine for prevention of motion sickness: clinical pharmacokinetics and therapeutic applications |journal=Clinical Pharmacokinetics |volume=45 |issue=6 |pages=543–66 |year=2006 |pmid=16719539 |doi= 10.2165/00003088-200645060-00001|s2cid=31285768 }}</ref>
* The anti-hypertensive drug [[clonidine]] is available in transdermal patch form.<ref name="pmid8162656">{{cite journal |vauthors=Berner B, John VA |title=Pharmacokinetic characterisation of transdermal delivery systems |journal=Clinical Pharmacokinetics |volume=26 |issue=2 |pages=121–34 |date=February 1994 |pmid=8162656 |doi= 10.2165/00003088-199426020-00005|s2cid=25273356 }}</ref> 
* [[Emsam]], a transdermal form of the [[Monoamine oxidase inhibitor|MAOI]] [[selegiline]], became the first transdermal delivery agent for an [[antidepressant]] approved for use in the U.S. in March 2006.<ref name="Emsam">{{cite web|url=http://www.medpagetoday.com/Psychiatry/Depression/2764|title=FDA Approves First Antidepressant Transdermal Patch|date=2006-03-01|access-date=2010-09-28|author=Peck, Peggy}}</ref>
* [[Daytrana]], the first [[methylphenidate]] transdermal delivery system for the treatment of [[attention deficit hyperactivity disorder]] (ADHD), was approved by the FDA in April 2006.<ref name="Daytrana">{{cite web|url=http://www.medicalnewstoday.com/articles/41333.php|title=Transdermal Patch Approved For Treatment Of ADHD|author=Cabray, Matthew|date=2006-04-12|access-date=2010-09-28}}</ref>
* [[Secuado]], a transdermal form of the [[atypical antipsychotic]] [[asenapine]], was approved by the FDA in October 2019.<ref name="Carrithers 2020">{{cite journal | last1=Carrithers | first1=Brennan | last2=El-Mallakh | first2=Rif S | title=Transdermal Asenapine in Schizophrenia: A Systematic Review | journal=Patient Preference and Adherence | volume=14 | date=18 March 2020 | pages=1541–1551 | pmid=32943849 | doi=10.2147/PPA.S235104 | pmc=7468370 | doi-access=free }}</ref>
* [[5-Hydroxytryptophan]] (5-HTP) can also be administered through a transdermal patch, which was launched in the United Kingdom in early 2014.<ref>{{cite web|url=http://5htppatch.co.uk |title='Revolutionary' 24-hour slow release 5-HTP transdermal patch, launched in early 2014 in the United Kingdom |publisher=5htppatch.co.uk |access-date=2014-06-18}}</ref>
* [[Rivastigmine]], an [[Alzheimer's disease|Alzheimer's]] treatment medication, was released in patch form in 2007 under the brand name Exelon.<ref name="Exelon">
{{cite web |url=http://www.medpagetoday.com/ProductAlert/Prescriptions/6119 |title=Medical News: FDA Approves Rivastigmine Patch for Alzheimer's Disease |author=Peck, Peggy |date=2007-07-10 |access-date=2011-03-10}}</ref>
* In December 2019, [[Robert S. Langer]] and his team developed and patented a technique whereby transdermal patches could be used to label people with invisible ink in order to store medical information subcutaneously. This was presented as a boon to "developing nations" where lack of infrastructure means an absence of medical records.<ref name="atmit">{{cite news |last1=Trafton |first1=Anne |title=Storing medical information below the skin's surface |url=https://news.mit.edu/2019/storing-vaccine-history-skin-1218 |publisher=MIT News |date=18 December 2019}}</ref><ref name="jaklenec19">{{cite news |last1=Jaklenec |first1=Ana |last2=McHugh |first2=Kevin J. |last3=Langer |first3=Robert S. |title=Microneedle tattoo patches and use thereof |url=https://patents.google.com/patent/US20190015650A1/en |issue=US20190015650A1 |publisher=US Patent and Trademark Office}}</ref> The technology uses a "[[quantum dot dye]] that is delivered along with a [[vaccine]]".<ref name=atmit/>
* [[Caffeine patch]]es, designed to deliver [[caffeine]] to the body through the skin.<ref>{{Cite web|last=DiLella|first=Chris|date=2016-09-23|title=Start-up: Don't drink your coffee — wear it!|url=https://www.cnbc.com/2016/09/23/start-up-dont-drink-your-coffee--wear-it.html|access-date=2021-10-14|website=CNBC|language=en}}</ref>